王樹森

第一個方向主要涉及的是乳腺癌臨牀研究方面的內容；這方面研究的目的意在探索如何優化乳腺癌的內科治療以期提高乳腺癌的內科治療水平；第二個方向的研究涉及到的是腫瘤信號傳導通路中的相關因子在腫瘤的發生、發展及預後方面的探索研究，這方面的研究目的意在探索腫瘤發生、發展的機制，期待發現新的干預以及治療靶點。在臨牀研究方面，作為設計者及發起者主持了全國多中心的臨牀研究10項，主持新藥一期臨牀研究6項，參與了國際以及國內多中心臨牀研究多項。在這些參與的臨牀研究中如BOLERO系列研究以及BETH、BRTRICE等研究對乳腺癌指南的制定以及乳腺癌的臨牀實踐產生了重要的影響；發起的FANCY研究是探索氟維司羣用於絕經後激素受體陽性乳腺癌患者一線治療後維持治療的療效及安全性的多中心、前瞻性研究，這一研究填補了內分泌維持治療缺乏前瞻性研究數據的這一空白。第二個研究方向上，在三陰性乳腺癌的分子機制及靶向治療方面開展了系列研究，發現BRCA1轉錄調控天冬氨酸代謝的分子機制，揭示CDK4/6抑制劑耐藥的具體機制，描繪了三陰性乳腺癌的免疫微環境單細胞圖譜，探索並揭示了三陰性乳腺癌內在異質性和轉移路徑關鍵信號通路。 ^[7] 

中國抗癌協會腫瘤內分泌專委會副主任委員

中國研究型醫院協會乳腺癌專業委員會副主任委員

中國抗癌協會乳腺癌專業委員會常務委員

中國臨牀腫瘤協會乳腺癌專業委員會常務委員

中國抗癌協會腫瘤臨牀化療專業委員會青委會副主任委員

國家腫瘤質控中心乳腺癌質控專業委員會委員

中國乳腺癌篩查與早診早治指南專家委員會委員

國家衞健委乳腺癌合理用藥指南專家委員會委員

廣東省胸部腫瘤防治研究會乳腺癌專業委員會主任委員

廣東省抗癌協會乳腺癌專業委員會副主任委員

廣東省醫師協會乳腺專科工作委員會副主任委員

廣東省抗癌協會化療專業委員會副主任委員。 ^[1] 

1.Tao Qin, Yinduo Zeng, Qianyi Lu, Xinke Zhang, Ge Qin, Qiufan Zheng,Fei Xu,Roujun Peng, Zhongyu Yuan and Shusen Wang. Nomogram Model of LNR Predicts Survival in Premenopausal.Anticancer Research 37:4575-4586(2017).(corresponding author)

2.Zheng Qiufan,Xia Wen,Lu Qianyi,Hong Ruoxi,Qin Ge,Xu Fei,Qin Tao,Shi Yanxia,Yuan Zhongyu,Wang Shusen. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat,2016 Nov;160(2):197-209. (corresponding author)

3.Tao Qin,Yin-duo Zeng, Ge Qin, Fei Xu, Jia-bin Lu, Wen-feng Fang, Cong Xue, Jian-hua Zhan, Xin-ke Zhang, Qiu-fan Zheng, Rou-jun Peng, Zhong-yu Yuan, Li Zhang, Shu-sen Wang.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 6(32):2015,33972-81. (corresponding author)

4.Ge Qin, Fei Xu, Tao Qin, Qiufan Zheng, Dingbo Shi, Wen Xia, Yun Tian, Yanlai Tang, Jingshu Wang, Xiangshen Xiao, Wuguo Deng, Shusen Wang. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget, Advance Publications 2015,1-15. (corresponding author)

5.Qiufan Zheng, Fei Xu, Man Nie, Wen Xia, Tao Qin, Ge Qin, Xin An, Cong Xue, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Shusen Wang. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer. Medicine,2015,94(40):1-9. (corresponding author)

6.Tao Qin, Zhong-Yu Yuan, Rou-Jun Peng, Bing Bai, Yin-Duo Zeng, Yan-Xia Shi, Xiao-Yu Teng,Dong-Geng Liu, Shu-Sen Wang. Clinicopathologic characteristics and prognostic factorsfor HER2-positive patients with metastatic breastcancer in southern China. Arch Med 2015; 11, 3: 544–550.(corresponding author)

7.Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, Yu W, Dai M, Li Z, Yi C, Zhao S, Li M, Du S, Cheng W, Xiao X, Chen Y, Wu T, Meng S, Yuan Y, Liu Q, Huang W, Guo W, Wang S, Deng W. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.Oncotarget. Oncotarget. 2015 Apr 10;6(10):8046-61. (corresponding author)

8.Fu L, Shi K, Wang J, Chen W, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89 (corresponding author)

9.Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, Fu L, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas. Mol Oncol. 2014 May;8(3):704-716 (corresponding author)

10.ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua, LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene in Postmenopausal Operable Patients with Luminal Subtype of Breast Cancer as Compared with Tamoxifen:A Retrospective Study in China. Chin J Bases Clin General Surg, 2014,21( 5):555-561(corresponding author)

11.Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J Bases Clin General Surg, 2014, 21( 5):544-548(corresponding author)　

12.Qin T, Yuan ZY, Peng RJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9 (corresponding author)

13. Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47 (corresponding author)

14.QIN Tao, YUAN Zhong-yu, PENG Rou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with Luminal Subtype Early Breast Cancer： A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY（MEDICAL ENCES）,2013,34(3):402-406(corresponding author)

15.Fu ly, Chen WB, Guo W, Wang JS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS, Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13 (corresponding author)

16.Gu WG, Huang Y, Yuan ZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (corresponding author)

17.Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li, Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)

18.Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol. 2012,29:547-553 (first author)

19.He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol 2012,29:406-410

20.Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X, Qin T. EGFR expression correlates with decreased disease-free survival in triple negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol. 2012,29:401-405

21.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, An X, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Med Oncol 2012,29:39-47

22.Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714

23.Wang x, Wang SS, Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG, Yuan ZY. Interaction of coping styles and psychological stress on anxious and depressive symptoms in Chinese breast cancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. （IF：1.24）

24.Peng R, Wang S, Shi Y, Liu D, Teng X, Qin T, Zeng Y, Yuan Z. Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case-control study. Breast. 2011; 20: 568-573.（IF：2.089）

25.Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY. Interaction of Social Support and Psychological Stress on Anxiety and Depressive Symptoms in Breast Cancer Patients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. （IF：1.24）

26.Bing Bai, Shusen Wang et al. Clinical Features and Survival Analysis of Different Subtypes of Patients with Breast Cancer Brain Metastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author)

27.Qin jianyong Wang shusen,YIN CHUANZHONG The legal and ethic issues in operating medical information service website. JOURNAL OF MEDICAL INFORMATICS,2010,31(8):52-55

28.Yuan zhongyu,Shusen Wang, et al. Clinical Characteristics and Prognosis of Triple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal of Cancer, 2008, 27(6)..

29.Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis of different subtypes of breast cancer Chinese Journal of Oncology. 2008 ,30(6):456-61

30.Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20 expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma. Chinesr journal of cancer 2008,27(11):1197-1203

31.CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al. Primary Breast Lymphoma —A Report of 27 Cases with Literature Review Chinese Journal of Cancer, 2007, 26( 1) : 84- 89

32.Xiao Jian, Wang Shusen, Huang Yan et al. Expression of CD117 and PDGFRa in Extranodular NK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology 2,007 34(11):615-617

33.QIU Miao-Zhen, XU Fei, WANG Shu-Sen et al. Responses of 109 Adult Soft Tis sue Sarcoma Patients to Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349

34.Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expression in Nasopharyngeal Carcinoma，Chinese Journal of Oncology.2006,28(1).

35.Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1 Expression in Nasopharyngeal Carcinoma，Chinese Journal of Clinical Oncology，2005,32,(6)

36.Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor Gefitinib on Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2004,23(11s).

37.Yanqun Xiang, Shusen Wang, et al Prognostic Value of Surviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).

38.Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. Chinese Journal of Medicine.2004, 4(1): 24-29.

39.Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. Chinese Journal of Cancer Palliative Medicine. 2003,2(4): 239-242.

40.Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According to Good Clinical Practice. National Medical Journal of China.2003,83(3):179-180.

41.Shusen Wang , Ruilin Wang, et al. Study on the Purification of Angiogenesis Inhibitor from Shark Cartilage and its Biological Characteristics. Henan Journal of Oncololgy.1999, 12(3): 179-181.

42.Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 Endothelial Cells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998, 18 (3): 176-178.

43.Jinchuan Zhang, Shusen Wang, et al. Detecting Tumor Specific Growth Factor in Patients with Chemotherapy. Academiae Medicinae Xuzhou.2001, 21(2): 116-117.

44.Desheng liu, Shusen Wang et al. How to Improve the Effect and Safety of Three-Step Method of Analgesia. Chinese Journal of Clinical Oncology and Recovery.1999, 6 (5): 77-79.

在腫瘤學的教學中，王樹森特別強調腫瘤學的教學應以掌握腫瘤學的知識體系和提高臨牀應用的能力為目的，以臨牀思維能力的培養為核心，不斷優化教學模式，構建適應臨牀醫學和基礎醫學系統的完整的實驗教學體系，培養學生的操作能力、臨牀思維能力以及解決問題能力。在高等醫學教育中，王樹森是一位啓蒙者。在每一堂課上，總能看到他認真準備的教案課件。除了課本上的系統知識，王樹森還從臨牀實踐出發，帶領學生教學查房，認真為學生講解腫瘤學的相關病例知識。2020年，王樹森作為主編之一出版了教材《臨牀腫瘤學（clinical oncology）》，該教材是“十三五”國家重點圖書出版規劃項目和“一帶一路”背景下國際化臨牀醫學叢書，既是臨牀醫學實踐的專著，也是對臨牀醫學專家寶貴經驗的總結，反映了臨牀醫學技術的最新應用與進展。這本教材的順利出版，填補了我國在國際化臨牀醫學叢書的出版空白，為我國高層次的研究生教育以及國際留學生的教育提供了臨牀腫瘤學的教學樣板，也為提高我國腫瘤學教學水平起了積極的推動作用。近年，作為主要執筆者制定了中國晚期乳腺癌維持治療指南，王樹森參與了國家衞健委乳腺癌診療指南，國家腫瘤質控中心乳腺癌質控標準、中國抗癌協會乳腺癌專業委員會和中國臨牀腫瘤協會乳腺癌專業委員會等多項指南的制定，為我國乳腺癌的規範化診療發揮了重要作用。（中山大學腫瘤防治中心評） ^[6]